LKC Technologies has successfully completed a rigorous multi-center clinical trial, which designed to evaluate the effectiveness of RETeval based visual electrophysiology in assessing sight threatening diabetic retinopathy (DR) in comparison to the generally accepted gold standard for DR diagnosis.
LKC Technologies has successfully completed a rigorous multi-center clinical trial, which designed to evaluate the effectiveness of RETeval based visual electrophysiology in assessing sight threatening diabetic retinopathy (DR) in comparison to the generally accepted gold standard for DR diagnosis.
RETeval is a handheld DR screening device that enables virtually any health care provider to screen for sight-threatening DR in less than three minutes per patient with no dilation regardless of pupil size or the presence of a cataract.
LKC Technologies president James Datovech said the preliminary results are excellent.
"The medical, diabetic care and public health communities will find great value in this technology," Datovech added.
The study recruited over 400 diabetic patients and the primary investigator of the study was Dr Stephen Fransen, associate professor at the Dean McGee Eye Institute, University of Oklahoma and chief medical officer of Inoveon, a provider of ETDRS 7-field stereo fundus photography services.
Using skin electrodes (not corneal electrodes) and a simple handheld device, minimizes the cost and complexity of the DR screening equation, the company reported.
LKC also announces a new RETeval option at ARVO allowing RETeval to be a full function, hand-held, flash ERG/VEP device that will run the complete five and/or six step ISCEV flash ERG protocol using skin electrodes.
RETeval is CE marked and is already approved in Canada, Australia and Japan. Additionally, it is being used in a number of other countries including the UK, India, Canada, Indonesia and Malaysia.
Image: LKC Technologies’ RETeval Photo: courtesy of PRNewsFoto/LKC Technologies, Inc.